Flaxseed in Preventing Breast Cancer in Premenopausal Women at Risk of Developing Breast Cancer

* Patients enrolled in must meet ≥ 1 of the following criteria: * History of unilateral or bilateral atypical ductal hyperplasia with or without family history * History of atypical lobular hyperplasia or lobular carcinoma in situ with or without family history * History of ductal carcinoma in situ * Prior stage I breast cancer allowed provided it was adequately treated and therapy was completed ≥ 1 year ago * Lifetime risk for developing breast cancer \> 20% (based on Gail or Claus model) * No abnormal mammogram requiring short-term follow-up within the past 6 months * No severe atypia or carcinoma cells on RPRNA PATIENT CHARACTERISTICS: * Premenopausal * ECOG performance status 0-1 * Patients enrolled must meet the following criteria: * No peri- or postmenopausal status as determined by estradiol levels \< 20 ng/dL and FSH levels \> 45 ng/dL * No thrombocytopenia (defined as platelet count \< 50,000/mm\^3) * Creatinine ≤ 1.5 mg/dL * Not pregnant or nursing * Fertile patients must use effective contraception consistently * No other prior malignancy allowed except for the following: * Basal cell or squamous cell carcinoma * In situ cervical cancer * No history of any of the following conditions within the past 5 years: * Crohn disease * Ulcerative colitis * Inflammatory bowel disease * Irritable bowel syndrome * Celiac sprue * Malabsorption syndrome * Diverticulitis * Diverticulosis * No allergy to flaxseed, other seeds or nuts, or wheat PRIOR CONCURRENT THERAPY: * Patients enrolled in part 1 must meet the following criteria: * No prior breast implants or tram-flap reconstruction * Breast reduction allowed * No prior neoadjuvant chemotherapy or other chemotherapy within the past year * No prior neoadjuvant hormonal therapy * No prior whole radiation to the contralateral breast undergoing random periareolar fine needle aspiration (RPFNA) * No concurrent coumadin or other chronic anticoagulants (even if they are held for surgery) * Patients enrolled in part 2 must meet the following criteria: * More than 1 year since prior chemotherapy and adjuvant hormonal therapy for breast cancer * No concurrent chemotherapy for breast cancer * At least 1 month since prior and no concurrent treatment with corticosteroid * At least 2 weeks since prior and no concurrent use of antibiotics * At least 2 weeks * No history of chest wall irradiation * No presence of breast implants * No prior or concurrent tamoxifen within the past 90 days * No chronic/concurrent medications that inhibit platelet function, including any of the following: * Aspirin * Non-steroidal anti-inflammatory drugs (i.e., Aleve®, Motrin®, ibuprofen) * Coumadin * Heparin * Low molecular weight heparin * Anti-platelet agents * No prior short-term use of platelet inhibitors ≥ 7 days prior to RPFNA * No concurrent ingestion of the following: * Pumpkin seeds * Sesame seeds * Fish oil supplements * At least 30 days since prior and no concurrent flaxseed supplements, fish oil, or flaxseed oil * No concurrent treatment for another malignancy